Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
- 18 April 2024
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 44 (3) , 207-210
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Association between abdominal adiposity and cognitive decline in older adults: a 10-year community-based studyThe Journal of nutrition, health and aging, 2024
- GLP-1 agonists: A review for emergency cliniciansThe American Journal of Emergency Medicine, 2024
- Cotadutide (GLP-1/Glucagon dual receptor agonist) modulates hypothalamic orexigenic and anorexigenic neuropeptides in obese micePeptides, 2023
- The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-AnalysisThe American Journal of Geriatric Psychiatry, 2023
- Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort studyObesity Pillars, 2023
- Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activationMolecular Metabolism, 2021
- Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United StatesProgress in Cardiovascular Diseases, 2021
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum DisorderJAMA Psychiatry, 2017
- Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide – A pilot studyObesity Research & Clinical Practice, 2015
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes MellitusJAMA Internal Medicine, 2013